Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Increases By 62.7%

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 152,900 shares, a growth of 62.7% from the October 31st total of 94,000 shares. Based on an average daily volume of 395,000 shares, the short-interest ratio is presently 0.4 days. Approximately 3.3% of the shares of the stock are sold short.

Entero Therapeutics Stock Performance

ENTO stock opened at $0.45 on Friday. The company has a 50 day moving average of $0.51. Entero Therapeutics has a 1 year low of $0.19 and a 1 year high of $14.51.

Entero Therapeutics (NASDAQ:ENTO) last posted its quarterly earnings data on Monday, October 21st. The company reported ($3.37) EPS for the quarter. Analysts expect that Entero Therapeutics will post -1.13 earnings per share for the current year.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.